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ABSTRACT
Background Non- adherence to medications continues 
to be a burden worldwide, with significant negative 
consequences. Community pharmacist interventions seem 
to be effective at improving medication adherence. However, 
more evidence is needed regarding their impact on disease- 
specific outcomes. The aim was to evaluate the impact 
of a community pharmacist- led adherence management 
intervention on adherence and clinical outcomes in 
patients with hypertension, asthma and chronic obstructive 
pulmonary disease (COPD).
Methods A 6- month cluster randomised controlled 
trial was conducted in Spanish community pharmacies. 
Patients suffering from hypertension, asthma and COPD 
were recruited. Patients in the intervention group received 
a medication adherence management intervention and 
the control group received usual care. The intervention 
was based on theoretical frameworks for changing patient 
behaviour. Medication adherence, disease- specific outcomes 
(Asthma Control Questionnaire (ACQ) scores, Clinical COPD 
Questionnaire (CCQ) scores and blood pressure levels) and 
disease control were evaluated. A multilevel regression model 
was used to analyse the data.
Results Ninety- eight pharmacies and 1186 patients were 
recruited, with 1038 patients completing the study. Patients 
receiving the intervention had an OR of 5.12 (95% CI 3.20 
to 8.20, p<0.05) of being adherent after the 6 months. At 
the end of the study, patients in the intervention group had 
lower diastolic blood pressure levels (mean difference (MD) 
−2.88, 95% CI −5.33 to −0.43, p=0.02), lower CCQ scores 
(MD −0.50, 95% CI −0.82 to −0.18, p<0.05) and lower 
ACQ scores (MD −0.28, 95% CI −0.56 to 0.00, p<0.05) 
when compared with the control group.
Conclusions A community pharmacist- led medication 
adherence intervention was effective at improving 
medication adherence and clinical outcomes in patients 
suffering from hypertension, asthma and COPD. Future 
research should explore the implementation of these 
interventions in routine practice.
Trial registration number ACTRN12618000410257.
INTRODUCTION
Patients with chronic conditions rely on 
medications to treat and control their 
diseases.1 However, medication adher-
ence (ie, the process by which patients 
take their medications as prescribed) is 
suboptimal.2 Medication adherence is 
composed of initiation, implementation 
and discontinuation.3 4 There is evidence 
that nearly 40% of patients with chronic 
conditions discontinue their medication 
after 1 year and 4% never initiate their 
treatment.5 Similarly, implementation of 
the dosing regimen (ie, the extent to which 
a patient’s actual dosing corresponds to 
the prescribed dosing regimen) has been 
shown to decline over time.6 This complex 
phenomenon is a preventable7 source of 
patient harm and poor health outcomes. 
It often leads to disease progression, lower 
quality of life, increased use of healthcare 
resources8 and increased morbidity and 
mortality.9 10 It accounts for an estimated 
125 000 deaths per year in the USA,11 
with annual costs per patient ranging 
from $949 to $44 190 (US$2015).12 
This problem is especially relevant in 
chronic conditions such as hypertension, 
asthma and chronic obstructive pulmo-
nary disease (COPD), three of the most 
prevalent non- communicable diseases in 
developed countries, whose prevalence 
continues to increase.13–15 Medication 
non- adherence rates in these conditions 
are high, reaching 50% for antihyperten-
sive medications5 and between 20% and 
80% for inhaled medications,16 17 with 
14%–20% patients failing to fill in their 
first prescription.18
Medication adherence interventions 
have the potential to improve clinical 
outcomes, patient’s health- related quality 
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healthcare system.21–23 Long- term multicomponent 
interventions involving behavioural change theories 
seem promising at improving adherence,24–26 probably 
because they target multiple determinants.27 However, 
previous research has reported a lack of convincing 
evidence regarding the efficacy of these interventions, 
mainly due to the wide heterogeneity in settings, 
participants, intervention types or adherence measures 
among others. Moreover, there seems to be a paucity 
of randomised controlled trials reporting an improve-
ment in both adherence and clinical outcomes,28 despite 
ethical standards for adherence research dictating that 
attempts to improve adherence should be judged by 
their clinical benefits.28 In this regard, some evidence 
suggests that community pharmacist- led interventions 
may enhance both medication adherence29–32 and 
disease- specific clinical outcomes.33 34 However, these 
usually involve interventions that would be difficult 
to implement in usual care settings. The development 
of effective interventions that are implementable in 
routine practice settings still represents a challenge for 
quality improvement in patient care.35
Quality use of medicines is often included as a key 
objective in many national medicine policies, through 
the implementation of initiatives aiming at ensuring 
medicines are safely and effectively used. This usually 
includes mechanisms to monitor and manage medica-
tion adherence, which constitutes one of the overar-
ching goals to improve healthcare quality and patient 
safety.36 In Spain, adherence management is one of 
the six professional services with national priority 
following a consensus among Spanish national profes-
sional pharmacy organisations.37 However, there is a 
lack of evidence on the effectiveness of a medication 
adherence intervention that can be further imple-
mented into regular practice.
The objective of this study was to evaluate the effec-
tiveness of a community pharmacist- led medication 
adherence management intervention for adult patients 
being treated with hypertension, asthma or COPD 
medications on medication adherence and clinical 
outcomes compared with usual care.
METHODS
This study has been reported following the Consol-
idated Standards of Reporting Trials guidelines for 
cluster trials.38
Study design
A cluster randomised controlled trial was undertaken 
in community pharmacies across six Spanish provinces 
(A Coruña, Albacete, Ciudad Real, Guadalajara, Soria 
and Tenerife), representing about 12% of the prov-
inces and 7% of community pharmacies in Spain.39 
Pharmacies were the unit of randomisation to mini-
mise cross- contamination between study groups. A 
study protocol has been registered and approved by 
the Spanish Medication Agency (Agencia Española de 
Medicamentos, 4DZRC79213). No incentives were 
provided to pharmacists or patients.
Pharmacy recruitment
An invitation letter to enrol in the study was sent to 
all the pharmacies in each province by the local phar-
macy professional body. The inclusion criteria for 
pharmacies were: availability of a counselling area; 
availability of at least one pharmacist to provide the 
intervention; and the attendance of all pharmacists 
to an initial training session before the beginning 
of the study. Inclusion criteria were verified by the 
local pharmacy professional bodies and by members 
of the research team. Due to the nature of the inter-
vention, cluster randomisation was used to minimise 
cross- contamination between study groups. Eligible 
pharmacies were the unit of randomisation. They 
were assigned by an independent researcher after they 
agreed to participate in the study to either an inter-
vention group (IG) or control group (CG) using a 
computer- generated list of random numbers with ratio 
1:1.
Sample size calculation/sampling
Sample size calculations were based on the difference 
of expected proportions between adherent patients in 
CG and IG at the end of the study. An absolute differ-
ence of 20% in the prevalence of adherent patients 
between both groups was considered of clinical rele-
vance.40 41 A two- tailed comparison test was applied, 
considering an 80% power, alpha=0.05 and assuming 
a 50% prevalence of non- adherent patients at baseline.
The sample size was increased to take into 
account the design effect (DEFF), calculated as: 
DEFF=1+[nc−1]*ICC (intraclass correlation coeffi-
cient) (where nc=7, average size of the cluster esti-
mated for 102 clusters; ICC=0.05), resulting in 1025 
patients. This number was increased to account for 
a potential 20% loss to follow- up. Therefore, 1230 
patients and 102 pharmacies were estimated to be 
required. Each pharmacy was required to recruit 12 
patients: 4 suffering from hypertension, 4 from asthma 
and 4 from COPD.
Patient recruitment
Patients were recruited consecutively in the partic-
ipant community pharmacies for 2 months. Filling 
a prescription (for new or/and existing prescribed 
medications) was the prompt for the pharmacist to 
initiate a conversation about the study with poten-
tial eligible patients. Patients’ inclusion criteria were: 
18 years or older; signature of the informed consent; 
ability to complete EuroQol- 5D,42 Morisky- Green- 
Levine Medication Adherence Questionnaire (MGL 
MAQ),43 44 Asthma Control Questionnaire (ACQ)45 or 
Clinical COPD Questionnaire (CCQ)46; and to have 
a prescribed medication for hypertension (ie, medica-
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(ATC) classification system groups C02, C03, C07, 
C08 or C09), asthma or COPD (ATC group R03). 
Medication groups were defined as per the ATC clas-
sification system developed by the WHO.47 Hyperten-
sion, asthma and COPD were the target conditions due 
to their high prevalence and non- adherence rates.13–15 
If patients suffered from more than one of those 
diseases, data were only collected for one condition. 
This was selected by the pharmacist on the basis of the 
number of patients to be recruited per disease. Patients 
were excluded if they: were collecting someone else’s 
medication; were pregnant or lactating; could not 
attend the pharmacy on a regular basis; had previously 
participated in any adherence education programme 
or study; had communication limitations or any other 
impairment the recruiting pharmacist considered 
as precluding them from participating in the study. 
During recruitment, the pharmacist explained the 
general characteristics of the study (ie, study involving 
monthly visits to the pharmacy, in which patients had 
to respond to the pharmacist’s questions about their 
medications and health), assessed the patient’s willing-
ness to participate and their eligibility criteria. Patients 
were blinded to the study design, group and hypoth-
eses. Patients willing to participate received an infor-
mation sheet and their signed informed consent was 
obtained. Subsequently, the pharmacist and the patient 
agreed on a date for the initial and subsequent visits.
Patients attended six face- to- face monthly visits, 
undertaken in the pharmacy’s counselling area. Patients 
allocated to the IG received a protocolised medication 
adherence management intervention (figure 1) whereas 
patients in the CG received usual care (defined as the 
supply of medicines and medication- taking advice). 
In each visit, patients’ data were collected and clinical 
variables recorded.
Intervention group
Patients in the IG received the medication adherence 
management intervention. It involved the provision of 
a complex intervention,48 based on behaviour change 
frameworks, aiming at identifying and addressing 
barriers for medication adherence through tailored 
strategies. The intervention included:
1. Pharmacist interview to assess adherence to medica-
tions for asthma, COPD or hypertension using the MGL 
MAQ.43 44
2. Classification of patients as non- adherent (non- 
intentional, intentional or combined) or adherent.
3. Identification of barriers for medication adherence. Bar-
riers could be practical, defined as gaps in knowledge or 
skills; or perceptual, namely those associated with the 
patient’s health beliefs and perceptions about the condi-
tion and their medications.
4. Intervention proposal using strategies tailored to the type 
of non- adherence and identified barriers (online supple-
mental appendix 1).
5. Application of the transtheoretical model of behavioural 
change49 by which the pharmacist elicited the patient’s 
readiness to change while discussing the proposed strat-
egies.50
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6. Follow- up through monthly scheduled visits to review 
patient progress and provide feedback or new strategies 
to improve or maintain adherence.
7. Application of motivational interviewing principles and 
skills26 51 during the patient–pharmacist interaction.
Pharmacist training
Group and individualised training sessions were 
provided by the research team and by practice change 
facilitators (PCFs, external pharmacists who solved 
any problems or queries during the study through 
monthly visits and ensured compliance with the study 
protocol). Pharmacists in the IG received an initial 
training which covered the following topics: study 
protocol, management of the targeted conditions, 
frameworks for changing patient behaviour and educa-
tional skills to provide the intervention, over a 2- day 
session. Pharmacists in the CG were only trained in 
data collection and study procedures.
Study outcomes
Medication adherence (appropriate implementation of 
the dosing regimen) was the primary outcome, assessed 
by the MGL MAQ43 44 and reported as the percentage 
of adherent patients. Secondary outcomes included 
asthma control, COPD clinical health status and hyper-
tension control. Asthma control was assessed using the 
ACQ-5.45 Results were reported as mean ACQ scores 
(scale 0–6, with lower scores indicating a better clinical 
control) and as the percentage of controlled patients 
(ACQ ≤0.75). A difference of ≥0.5 in mean scores 
was considered clinically significant.52 COPD clinical 
health status was assessed using the CCQ.46 Results 
were reported as mean CCQ scores (scale 0–6, with 
lower scores indicating a better clinical control) and as 
the percentage of patients with low clinical impact of 
the disease (scores <1.0).53 A difference ≥0.4 between 
mean scores was considered clinically significant.54 In 
COPD, ‘disease control’ is not achieved, as normalisa-
tion of pulmonary function is not possible and patients 
may continue with exacerbations or limitations during 
daily life activities regardless of receiving treatment.55 
Hypertension control was assessed through systolic 
blood pressure (SBP) and diastolic blood pressure 
(DBP) levels using a Visomat (Roche) (two measures, 3 
min interval). Proportion of controlled patients (values 
<140 mm Hg/90 mm Hg)56 and mean blood pressure 
(BP) levels were reported. All outcomes were meas-
ured in all study visits.
EuroQol data were collected in order to assess the 
cost- utility of the service. Results will be reported 
elsewhere.
Blinding
Patients were blinded to the intervention but given the 
nature of the intervention pharmacists were not. Only 
pharmacists in the IG were trained in the skills and 
knowledge required to deliver the intervention.
Data collection and quality
Study data were collected in an electronic data 
collection form, accessible by individual pharmacists 
through a personal username and password. Pharma-
cists directly recorded patient demographic data and 
observer- reported outcomes not involving judgement 
(ie, BP levels). Patient- reported outcomes (ie, medi-
cation adherence, ACQ scores and CCQ scores) were 
directly collected from patients. They completed the 
questionnaires in the electronic data collection form, 
requesting assistance from the pharmacist if needed.
PCFs monitored the quality of data entry and had 
their own access to the electronic data collection form 
to ensure data were being collected according to the 
protocol instructions.57 Patient data were protected 
and exported as dissociated for the statistical analysis. 
Only deidentified data from patients, pharmacists and 
pharmacies were available to the study researchers.
Statistical analysis
Data were analysed using the software package SPSS 
statistics (V.25.0, SPSS) and SAS/STAT V.9.4 (SAS 
Institute). Baseline patient- level information was 
summarised by treatment arm. A multilevel regression 
model with three levels (pharmacies, patients, visits) 
was conducted. It included a random intercept to 
account for the clustering by pharmacy and a corre-
lation structure for the visits within patients, that 
accounted for changes in correlation of measurements 
over time (Toeplitz). A logistic regression model was 
used with this structure to estimate the ORs for the 
binary outcomes, and a similar linear mixed model was 
used for continuous outcomes. A likelihood ratio p 
value (for the overall effect of the variable across visits) 
and a Wald p value for the test of treatment at each 
time point were estimated. Estimated rates with lower 
and upper levels were calculated. All patients with 
data collected from at least two time points during the 
study were included in the analysis. Estimated popula-
tion margins were used to estimate the percentage of 
patients for binary outcomes and the average value for 
continuous outcomes by treatment and time period. 
Linear and generalised linear mixed models for the 
study outcomes were used, allowing for the assump-
tion of ‘missing- at- random’ (ie, missing contingent 
on values included in the regression model) without 
requiring imputation for the missing outcomes (online 
supplemental appendix 2).
RESULTS
A total of 98 pharmacies and 138 pharmacists were 
recruited. Four pharmacies and four pharmacists 
dropped out from the study before starting patient 
recruitment and two pharmacies and three pharma-
cists dropped out during the study (n=4 IG, n=2 
CG). Patient recruitment was undertaken by phar-
macists between October and November 2017, with 
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hypertension: 502) and 1038 patients (asthma: 333, 
COPD: 249, hypertension: 456) completing the study 
(87.5%). Two hundred and eighteen patients were 
ineligible due to exclusion criteria (figure 2). Baseline 
patient characteristics are described in table 1.
Medication adherence
At baseline, the percentages of adherent patients were 
39.1% (IG) and 44.3% (CG). For individual follow- up 
periods, significant differences between study groups 
were observed from visit 3 (p<0.05) to visit 6 (OR 
5.12, 95% CI 3.20 to 8.20, p<0.05) (online supple-
mental appendix 3, figure 3). Overall, the absolute 
increase in the percentage of adherent patients during 
the study was higher in the IG (51.8%) than in the 
CG (22.2%) (p<0.05). Disease- specific results are 
reported in the online supplemental appendix 4.
Clinical control
Hypertension
Mean baseline BP levels were similar in both study 
groups. Mean difference (MD) DBP between IG 
Figure 2 Flow chart of study participants. *Two hundred and eighteen patients were ineligible due to exclusion criteria: collecting someone else’s 
medication (83), were pregnant or lactating (10), could not attend to the pharmacy on a regular basis (75), had previously participated in any adherence 
education programme or study (19), had communication limitations or any other impairment the recruiting pharmacist considered as precluding them from 
participating in the study (31). **The difference of eight recruited pharmacies is due to pharmacies that had previously participated in the 2- month pilot 
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and CG became statistically significant after visit 5 
(p<0.05). At the end of the study, there was a signifi-
cant reduction in mean DBP in the IG when compared 
to the CG (MD −2.88, 95% CI −5.33 to −0.43, 
p=0.02). Changes on SBP were not statistically signif-
icant (MD −1.10, 95% CI −4.49 to 2.29, p=0.53) 
(online supplemental appendix 3). Mean baseline 
percentages of controlled patients were similar in both 
groups (IG=55.5%, CG=52.9%). These percentages 
increased in both groups, with no difference between 
groups at the end of the study (OR 1.22, 95% CI 0.78 
to 1.91, p=0.38) (online supplemental appendix 3, 
figure 3).
Asthma
Mean baseline ACQ scores were similar in the IG and 
CG (p=0.98). A gradual decrease was observed in both 
groups until reaching significant differences in visit 5, 
favouring the IG (p<0.05). Mean scores decreased 
0.53 (IG) and 0.26 points (CG) between baseline and 
visit 6. Only the diminution in the IG was clinically 
significant. At visit 6, mean ACQ scores were signif-
icantly lower in the IG (MD −0.28, 95% CI −0.56 
to 0.00, p<0.05), indicating a better asthma control 
(online supplemental appendix 3). Percentages of 
controlled patients at baseline were similar (IG: 37.3%; 
CG: 43.8%). Statistically significant differences were 
evident after visit 5. Percentages of controlled patients 
at the end of the study were significantly higher in the 
IG (72.0%) when compared with the CG (57.8%) (OR 
1.88, 95% CI 1.05 to 3.36, p=0.03) (online supple-
mental appendix 3) (figure 3).
Chronic obstructive pulmonary disease
Mean baseline CCQ scores were 1.79 (IG) and 2.10 
(CG) (p<0.05). Mean scores decreased in both groups 
across study visits, with significant differences being 
evident after visit 3 (p<0.05) (MD at visit 6 −0.50, 
95% CI −0.82 to 0.18, p<0.05) (online supplemental 








Age, mean±SD 64.0±15.4 63.9±15.6 64.0±15.5
Gender, n (%)
  Male 257 (46.5) 303 (47.9) 560 (47.2)
  Female 296 (53.5) 330 (52.1) 626 (52.8)
Education, n (%)
  No studies 129 (23.3) 146 (23.1) 275 (23.2)
  Primary 201 (36.3) 258 (40.8) 459 (38.7)
  High school 125 (22.6) 151 (23.9) 276 (23.3)
  Vocational degree 13 (2.4) 9 (1.4) 22 (1.9)
  University 85 (15.4) 69 (10.9) 154 (13.0)
Working status, n (%)
  Paid employment 137 (24.8) 138 (21.8) 275 (23.2)
  Paid employment but 
on sick leave
13 (2.4) 21 (3.3) 34 (2.9)
  Unemployed 51 (9.2) 62 (9.8) 113 (9.5)
  Retired 320 (57.9) 374 (59.1) 694 (58.5)
  Student 32 (5.8) 38 (6.0) 70 (5.9)
Clinical condition, n (%)
  Hypertension 219 (39.6) 283 (44.7) 502 (42.3)
  Asthma 180 (32.5) 205 (32.4) 385 (32.5)
  COPD 154 (27.8) 145 (22.9) 299 (25.2)
Medications prescribed 
for the studied disease*, 
mean (SD)
1.84 (0.98) 1.91 (1.08) 1.88 (1.04)
Total number of 
prescribed medications, 
mean (SD)
5.72 (3.48) 5.69 (3.32) 5.71 (3.39)
Total number of 
diseases†, mean (SD)
2.58 (1.45) 2.55 (1.37) 2.57 (1.41)
*Hypertension, asthma or COPD.
†Number of all chronic diseases per patient.
COPD, chronic obstructive pulmonary disease.
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appendix 3). A reduction of 0.39 (CG) and 0.58 (IG) 
points in the mean scores was observed at the end 
of the 6- month period, with the latter being clini-
cally significant. At baseline, percentages of patients 
with low clinical impact of the disease (ie, low level 
of symptoms) were 20.6% (IG) and 16.3% (CG) at 
baseline (figure 3). These percentages increased across 
study visits in both groups, with significant differences 
favouring the IG after visit 3 (p<0.05). At the end of 
the study, the percentage of patients with low clinical 
impact of COPD was significantly larger in the IG (OR 
2.01, 95% CI 1.07 to 3.75, p<0.05) (online supple-
mental appendix 3).
DISCUSSION
A community pharmacist- led medication adherence 
management intervention resulted in improvements in 
medication adherence and clinical outcomes. Signifi-
cant increases in the percentage of patients adhering 
to their dosing regimen and improvements in COPD 
outcomes were evident after 3 months of follow- up. 
In the case of asthma outcomes and DBP significant 
improvements were observed after 5 months.
The observed baseline percentage of adherent 
patients, close to 50%, aligned with the figures previ-
ously reported by the WHO.58 Interestingly, there was 
a gradual increase in these percentages, reaching statis-
tically significant differences between study groups at 
visit 3. The percentage of adherent patients in the CG 
was found to remain constant during the following 
visits, always below 70%. In the IG, this percentage 
progressively increased during all study visits. At the 
end of the study, 90% of patients were adherent to 
their medications, doubling the baseline percentage 
in the IG and being nearly 25% more than in the 
CG. Previous studies assessing the effectiveness of 
pharmacists’ interventions using a similar follow- up 
period have found between 10% and 40% increase 
in the percentage of adherent patients.17 59 60 One 
study targeted patients using new prescribed medi-
cations and found a 10% increase in the percentage 
of adherent patients after 10 weeks of follow- up, but 
decreased after 26 weeks.61 This study consisted of one 
initial consultation and one follow- up consultation 5 
weeks later.61 Our study resulted in a larger increase 
(51.8%), probably due to the core components of the 
brief complex intervention, continuous follow- up and 
fidelity monitoring of the intervention provision.
These results highlight the importance of contin-
uous follow- up in medication adherence manage-
ment. Evidence supports that interventions provided 
on a regular basis are more likely to increase adher-
ence than a single intervention, signalling adherence 
management interventions are to be maintained as 
long as the treatment is needed.28 Similarly, interven-
tions delivered across multiple visits are more effec-
tive than those delivered during a single visit.62 Our 
results align with these findings, suggesting adherence 
interventions should be delivered for at least 3 months 
to be effective.
There is evidence in the literature indicating that 
pharmacist- led interventions improve medication 
adherence in patients with asthma, COPD and hyper-
tension.32 63 However, limited information exists 
regarding the description of effective interventions, 
making it difficult to replicate these in real practice. 
There has been a call to generate more evidence on 
the impact of these interventions on disease- specific 
clinical outcomes.28 Due to the negative impact medi-
cation non- adherence has on the patient’s outcomes, 
adherence management has been considered a key 
element in the development of quality improvement 
initiatives.35 Moreover, monitoring patient outcomes 
and medication management skills are essential when 
delivering interventions aiming at improving quality 
and safe medicines use.64
Core components of the intervention were based on 
evidence- based behaviour change frameworks to tailor 
specific patient needs and elicit medication adherence 
improvement. Including cognitive- based behaviour 
techniques resulted in adherence improvements.65 A 
recent meta- analysis stated the importance of cogni-
tive and behavioural components to effectively change 
adherence behaviour.25 However, there is no evidence 
supporting that a single theory should be used.66 
We considered a range of strategies tailored to each 
patient’s individual needs, including educational 
components or reminders, as they have shown to be 
effective in chronic conditions,67 68 such as hyperten-
sion.69 Our findings align with previous studies, which 
have shown increases in medication adherence and 
decreases in BP levels.41 60 70 71 Although our interven-
tion resulted in a larger increase in the proportion of 
controlled patients in the IG (12.8%) when compared 
with the CG, differences between study groups were 
not statistically significant at the end of the study. This 
could be due to the low mean baseline BP levels of 
included patients and to uncontrolled hypertension 
not being a patient inclusion criterion. Additionally, 
BP changes may also take longer to manifest, as differ-
ences in DBP levels started to be significant after 5 
months of follow- up. Consistent with other studies 
that reported reductions of 3–11 mm Hg (DBP) and 
7–30 mm Hg (SBP),41 60 71–74 our study reported a 
reduction of 3.3 mm Hg in SBP and 2.5 mm Hg in 
DBP levels. Non- adherence has been associated with 
a high DBP, thereby an improvement of medication 
adherence can positively impact in DBP and hyperten-
sion control.75–77
Pharmacists’ interventions in patients with respi-
ratory conditions such as counselling and education 
have also found to be effective at improving clinical 
outcomes.33 Our proposed intervention resulted in a 
larger increase in the percentage of controlled patients 
(34.7%), when compared with previous studies that 
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in mean ACQ scores was clinically significant52 and 
similar to previous studies.17 78 Similarly, an improve-
ment on the average score and percentage of patients 
with low clinical impact of COPD was observed. Unlike 
previous studies,40 79 our intervention resulted in clin-
ically54 and statistically significant differences in mean 
CCQ scores from visit 3 until the end of the study, 
indicating the intervention was effective at improving 
clinical outcomes in patients with COPD.
To the best of our knowledge, this is the first study 
proposing a medication adherence management inter-
vention in community pharmacies in Spain using 
complex interventions based on theories and frame-
works of behaviour change and reporting clinical 
outcomes; targeting one of the priority Spanish phar-
macy services37 and one of the key goals of health-
care.35 The novelty of this study is the proposal of a 
structured patient- tailored pharmacist intervention 
based on evidence- based frameworks25 and assessment 
of clinical variables in a community pharmacy setting. 
Although there is some evidence supporting the use of 
these frameworks in patients suffering from hyperten-
sion, it is limited for patients with asthma or COPD.
Practice implications
Findings of this study provide evidence on the effec-
tiveness of a patient- targeted intervention and support 
the future implementation of a medication adherence 
management service in regular practice.
Limitations
Objective adherence measures such as dispensing data 
could not be used. There was a lack of interoperability 
between pharmacies hindering the access to dispensing 
records. Therefore, only implementation adherence 
through a self- reported method was assessed, which 
may have been affected by desirability bias. Nonethe-
less, in the absence of a gold standard,80 patient self- 
reported questionnaires have a close correlation with 
electronic monitoring devices.81 Due to the nature of 
the intervention, pharmacist blinding was impossible. 
This is common in studies evaluating educational 
interventions. The intervention’s design required the 
collection of data as part of the patient’s evaluation 
and the provision of the intervention. Therefore, it 
was impossible to include a blinded data collector. 
Blinding personnel and intervention providers is often 
not achievable for studies assessing educational inter-
ventions. Potential risk of bias derived from lack of 
blinding for pharmacists was minimised, as the main 
study outcomes were either participant- reported 
outcomes (ie, patients who were blinded to the study 
group) or observer- reported outcomes not involving 
judgement.
Positive effects were also observed in the CG for 
medication adherence, asthma and COPD control 
during the first 2 months of study. Patients often modify 
their behaviour when feeling observed (ie, Hawthorne 
effect). Moreover, data collection could have made 
patients more conscious of their behaviours and have 
impacted their health. Finally, control pharmacists 
may have provided more information than they would 
provide during usual care, even if they were instructed 
not to change their regular practice.
CONCLUSION
A structured patient- targeted intervention based on 
behavioural change frameworks and the assessment of 
clinical variables proved to be effective at improving 
medication adherence and disease- specific clinical 
outcomes in patients with hypertension, asthma and 
COPD. Overall, intergroup differences were signif-
icant after 3 months of follow- up, highlighting the 
importance of continuous monitoring in the manage-
ment of medication adherence. This study proposes 
an approach to address patient safety and quality of 
care through adherence management. Integrating 
prescribing and pharmacy data would increase the 
potential of the intervention by measuring all dimen-
sions of medication adherence. Future research should 
explore the implementation of these interventions in 
routine practice.
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